Boehringer's anti-clotting drug Pradaxa gains EU approval

08/4/2011 | Reuters

The European Commission approved Boehringer Ingelheim's Pradaxa for preventing stroke in people with atrial fibrillation. The approval underscores Boehringer's lead over other drugmakers in replacing anticoagulant warfarin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC